Drug-Induced Cough

Shim, Ji-Su; Song, Woo-Jung; Morice, Alyn H.

doi:10.33549/physiolres.934406

Cited by 20 publications

(6 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dyspnoea and cough are common in patients with SSc-ILD [3][4][5][6][7] and have a negative impact on patients' quality of life [4,[8][9][10]. Cough in patients with SSc-ILD may be due to the SSc-ILD itself [4][5][6], to gastroesophageal reflux disease (GERD) [11,12], to other comorbidities [13], or to medication use [14]. Similarly, dyspnoea is a common manifestation of ILD, but may also occur due to comorbidities such as pulmonary hypertension or cardiac involvement [15,16].…”

Section: Introductionmentioning

confidence: 99%

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial

et al. 2022

View full text Add to dashboard Cite

Objective To investigate the rate of decline in forced vital capacity (FVC) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) with and without cough or dyspnoea in the SENSCIS trial. Methods Patients in the SENSCIS trial were randomized to receive nintedanib or placebo. Subgroups with and without cough or dyspnoea at baseline were defined by responses to the St. George’s Respiratory Questionnaire. Results At baseline, 114/575 patients (19.8%) did not have cough and 172/574 patients (30.0%) did not have dyspnoea. In the placebo group, the rate of FVC decline over 52 weeks was similar in patients with and without cough (-95.6 and -83.4 ml/year, respectively) or dyspnoea (-95.8 and -87.7 ml/year, respectively). The effect of nintedanib vs placebo on reducing the rate of FVC decline was numerically more pronounced in patients without than with cough (difference: 74.4 [95% CI -11.1, 159.8] vs 31.5 [-11.1, 74.1]) and without than with dyspnoea (79.8 [9.8, 149.7] vs 25.7 [-19.9, 71.3]), but interaction p-values did not indicate heterogeneity in the treatment effect between these subgroups (p= 0.38 and p= 0.20, respectively). Conclusion In the placebo group of the SENSCIS trial, the rate of FVC decline was similar irrespective of the presence of cough or dyspnoea at baseline. The effect of nintedanib on reducing the rate of FVC decline was numerically more pronounced in patients without than with cough or dyspnoea at baseline, but no statistically significant heterogeneity was observed between the subgroups. Trial registration ClinicalTrials.gov, https://clinicaltrials.gov, NCT02597933

show abstract

Section: Introductionmentioning

confidence: 99%

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Three of our patients with abnormally high hourly cough rates (39, 15, and 6 each) were using ACE inhibitors, which are known to induce cough in a proportion of patients [37]. For medical reasons, ACE inhibitors could not be discontinued to monitor cough in this study.…”

Section: Discussionmentioning

confidence: 99%

“…For medical reasons, ACE inhibitors could not be discontinued to monitor cough in this study. The cough-inducing effect of ACE inhibitors affects on average only 10% of patients and generally wanes several days or weeks after the medication has been introduced [37]. Nevertheless, future research should account for the potential influence of ACE inhibitor use on cough frequency.…”

Section: Discussionmentioning

confidence: 99%

Predictive Value of Cough Frequency in Addition to Aspiration Risk for Increased Risk of Pneumonia in Dysphagic Stroke Survivors: A Clinical Pilot Study

et al. 2021

View full text Add to dashboard Cite

Background: Post-stroke dysphagia leads to increased risk of aspiration and subsequent higher risk of pneumonia. It is important to not only diagnose post-stroke dysphagia early but also to evaluate the protective mechanism that counteracts aspiration, i.e., primarily cough. The aim of this study was to investigate the predictive value of cough frequency in addition to aspiration risk for pneumonia outcome. Methods: This was a single-center prospective observational study. Patients with first-ever strokes underwent clinical swallowing evaluation, fibreoptic endoscopic evaluation of swallowing (FEES), and overnight cough recording using LEOSound® (Löwenstein Medical GmbH & Co. KG, Bad Ems, Germany ). Penetration–Aspiration Scale (PAS) ratings and cough frequency measurements were correlated with incidence of pneumonia at discharge. Results: 11 women (37%) and 19 men (63%), mean age 70.3 years (SD ± 10.6), with ischemic stroke and dysphagia were enrolled. Correlation analysis showed statistically significant relationships between pneumonia and PAS (r = 0.521; p < 0.05), hourly cough frequency (r = 0,441; p < 0.05), and categories of cough severity (r = 0.428 p < 0.05), respectively. Logistic regression showed significant predictive effects of PAS (b = 0.687; p = 0.014) and cough frequency (b = 0.239; p = 0.041) for pneumonia outcome. Conclusion: Cough frequency in addition to aspiration risk was an independent predictor of pneumonia in dysphagic stroke survivors.

show abstract

“…ARBs function by blocking AT1R, preventing the binding of Ang II with this receptor ( 81 ). This specific blockade by ARBs reduces adverse effects secondary to kinins and substance P accumulation (degraded by ACE under physiological conditions) like cough and angioedema, more frequent in patients receiving ACEIs ( 82 ).…”

Section: Renin-angiotensin System-based Drugsmentioning

confidence: 99%

The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer

et al. 2021

View full text Add to dashboard Cite

Cancer is a complex group of diseases that constitute the second largest cause of mortality worldwide. The development of new drugs for treating this disease is a long and costly process, from the discovery of the molecule through testing in phase III clinical trials, a process during which most candidate molecules fail. The use of drugs currently employed for the management of other diseases (drug repurposing) represents an alternative for developing new medical treatments. Repurposing existing drugs is, in principle, cheaper and faster than developing new drugs. Antihypertensive drugs, primarily belonging to the pharmacological categories of angiotensin-converting enzyme inhibitors, angiotensin II receptors, direct aldosterone antagonists, β-blockers and calcium channel blockers, are commonly prescribed and have well-known safety profiles. Additionally, some of these drugs have exhibited pharmacological properties useful for the treatment of cancer, rendering them candidates for drug repurposing. In this review, we examine the preclinical and clinical evidence for utilizing antihypertensive agents in the treatment of cancer.

show abstract

Drug-Induced Cough

Cited by 20 publications

References 98 publications

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial

Predictive Value of Cough Frequency in Addition to Aspiration Risk for Increased Risk of Pneumonia in Dysphagic Stroke Survivors: A Clinical Pilot Study

The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer

Contact Info

Product

Resources

About